-
Tytuł:
-
Changes in benzodiazepine use in the French general population after November 2015 terrorist attacks in Paris: an interrupted time series analysis of the national CONSTANCES cohort.
-
Autorzy:
-
Gouraud C; Centre Ambulatoire d'Addictologie, AP-HP.Centre-Université de Paris, Hôpital européen Georges-Pompidou, Paris, France .
Airagnes G; Centre Ambulatoire d'Addictologie, AP-HP.Centre-Université de Paris, Hôpital européen Georges-Pompidou, Paris, France.
Kab S; UMS 011, Population-based Epidemiological Cohorts, INSERM, Villejuif, France.
Courtin E; Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, London, UK.
Goldberg M; UMS 011, Population-based Epidemiological Cohorts, INSERM, Villejuif, France.
Limosin F; Service de Psychiatrie de l'adulte et du sujet âgé, AP-HP.Centre-Université de Paris, Paris, France.; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Université de Paris, INSERM, Paris, France.
Lemogne C; Service de Psychiatrie de l'adulte et du sujet âgé, AP-HP.Centre-Université de Paris, Paris, France.; Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Université de Paris, INSERM, Paris, France.
Zins M; UMS 011, Population-based Epidemiological Cohorts, INSERM, Villejuif, France.
-
Źródło:
-
BMJ open [BMJ Open] 2021 Sep 17; Vol. 11 (9), pp. e044891. Date of Electronic Publication: 2021 Sep 17.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
-
MeSH Terms:
-
Benzodiazepines*/adverse effects
Terrorism*
Cohort Studies ; Female ; Humans ; Interrupted Time Series Analysis ; Paris/epidemiology
-
References:
-
J Trauma Dissociation. 2005;6(2):69-84. (PMID: 16150670)
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167. (PMID: 28756037)
J Clin Med. 2018 Jan 30;7(2):. (PMID: 29385766)
J Clin Pharm Ther. 2002 Aug;27(4):299-309. (PMID: 12174032)
Psychiatry Res. 2013 Dec 30;210(3):1301-3. (PMID: 24135551)
JAMA. 2002 Aug 7;288(5):581-8. (PMID: 12150669)
Prim Care Companion CNS Disord. 2017 Mar 2;19(2):. (PMID: 28257172)
Neuropsychopharmacology. 2016 Jan;41(1):357-69. (PMID: 26315508)
Am J Psychiatry. 2004 Aug;161(8):1384-9. (PMID: 15285963)
Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1101-10. (PMID: 19688727)
J Clin Psychiatry. 2018 Mar/Apr;79(2):. (PMID: 29659210)
Int J Epidemiol. 2017 Feb 1;46(1):348-355. (PMID: 27283160)
BMJ. 2015 Jun 09;350:h2750. (PMID: 26058820)
Lancet. 2011 Sep 3;378(9794):925-34. (PMID: 21890057)
Sci Adv. 2019 Apr 17;5(4):eaav3502. (PMID: 31001584)
Eur J Epidemiol. 2015 Dec;30(12):1317-28. (PMID: 26520638)
Br J Clin Pharmacol. 2014 Feb;77(2):295-301. (PMID: 22882333)
N Engl J Med. 2002 Mar 28;346(13):982-7. (PMID: 11919308)
CMAJ. 1989 Nov 1;141(9):917-21. (PMID: 2804849)
JAMA. 2002 Sep 11;288(10):1235-44. (PMID: 12215130)
J Psychiatr Pract. 2015 Jul;21(4):281-303. (PMID: 26164054)
Lancet. 2015 Dec 19;386(10012):2535-8. (PMID: 26628327)
CNS Spectr. 2005 Feb;10(2):107-15. (PMID: 15685121)
JAMA Psychiatry. 2015 Feb;72(2):136-42. (PMID: 25517224)
J Trauma Stress. 2014 Oct;27(5):618-21. (PMID: 25258255)
Eur J Public Health. 2013 Oct;23(5):732-6. (PMID: 23804080)
Br J Psychiatry. 2018 Apr;212(4):207-214. (PMID: 29557760)
J Clin Epidemiol. 2011 Nov;64(11):1252-61. (PMID: 21640554)
Addiction. 2011 Dec;106(12):2086-109. (PMID: 21714826)
Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):647-58. (PMID: 19418468)
BMC Public Health. 2019 May 14;19(1):566. (PMID: 31088561)
J Affect Disord. 2008 Sep;110(1-2):84-93. (PMID: 18329721)
N Engl J Med. 2001 Nov 15;345(20):1507-12. (PMID: 11794216)
-
Grant Information:
-
MR/T032499/1 United Kingdom MRC_ Medical Research Council
-
Contributed Indexing:
-
Keywords: mental health; preventive medicine; public health; substance misuse
-
Substance Nomenclature:
-
12794-10-4 (Benzodiazepines)
-
Entry Date(s):
-
Date Created: 20210918 Date Completed: 20211020 Latest Revision: 20220323
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8451294
-
DOI:
-
10.1136/bmjopen-2020-044891
-
PMID:
-
34535472
-
Objectives: To determine whether the terrorist attacks occurring in Paris on November 2015 have changed benzodiazepine use in the French population.
Design: Interrupted time series analysis.
Setting: National population-based cohort.
Participants: 90 258 individuals included in the population-based CONSTANCES cohort from 2012 to 2017.
Outcome Measures: Benzodiazepine use was evaluated according to two different indicators using objective data from administrative registries: weekly number of individuals with a benzodiazepine delivered prescriptions (BDP) and weekly number of defined daily dose (DDD). Two sets of analyses were performed according to sex and age (≤50 vs >50). Education, income and area of residence were additional stratification variables to search for at-risk subgroups.
Results: Among women, those with younger age (incidence rate ratios (IRR)=1.18; 95% CI=1.05 to 1.32 for BDP; IRR=1.14; 95% CI=1.03 to 1.27 for DDD), higher education (IRR=1.23; 95% CI=1.03 to 1.46 for BDP; IRR=1.23; 95% CI=1.01 to 1.51 for DDD) and living in Paris (IRR=1.27; 95% CI=1.05 to 1.54 for BDP) presented increased risks for benzodiazepine use. Among participants under 50, an overall increase in benzodiazepine use was identified (IRR=1.14; 95% CI=1.02 to 1.28 for BDP and IRR=1.12; 95% CI=1.01 to 1.25 for DDD) and in several strata. In addition to women, those with higher education (IRR=1.22; 95% CI=1.02 to 1.47 for BDP), lower income (IRR=1.17; 95% CI=1.02 to 1.35 for BDP) and not Paris residents (IRR=1.13; 95% CI=1.02 to 1.26 for BDP and IRR=1.13; 95% CI=1.03 to 1.26 for DDD) presented increased risks for benzodiazepine use.
Conclusion: Terrorist attacks might increase benzodiazepine use at a population level, with at-risk subgroups being particularly concerned. Information and prevention strategies are needed to provide appropriate care after such events.
Competing Interests: Competing interests: CG, EC, MG and MZ have no conflict of interest to report. GA has received speakers and/or consulting fees from Pfizer, Lundbeck and Pierre Fabre. CL has received speakers and/or consulting fees from Boehringer Ingelheim, Janssen, Lundbeck and Otsuka Pharmaceutical. FL has received speaker and/or consulting fees from AstraZeneca, Lundbeck, Janssen, Roche, Servier and Otsuka Pharmaceuticals.
(© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
